| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | necrostatin-7 | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.0023 | 0.9 |